Primordial Genetics and Pelican Technology Holdings merge to launch Primrose Bio $15 million Receive funding from Ligand Pharmaceuticals
san diego, September 18, 2023 /PRNewswire/—— Primula Bio Ltd, Primordial Genetics, Inc. and Pelican Technology Holdings, Inc. merge to form an independent, privately held biotechnology company focused on developing state-of-the-art protein and nucleic acid drug discovery and production systems.As part of the transaction, Ligand Pharmaceuticals contributed $15 million In terms of funding.
Primrose Bio combines Function Generator™ and Pelican expression technology® (formerly Pfenex Expression Technology®), its founding company’s platform, creates an innovative system to design and improve biological productivity to enable next-generation therapeutics. Function Generator systematically generates tens of millions of new genes in an ultra-high-throughput manner, enabling the discovery of proteins and microorganisms with improved functions. The Pelican Expression Technology Platform is a robust and scalable protein production system for five approved drugs that enables large-scale production of therapeutics and proteins, especially those that are complex and difficult to produce.
“We are excited to bring together two powerful technologies and two talented teams to create a company capable of delivering significant value to our pharmaceutical customers. Our combined technologies deliver unprecedented results at a speed and scale unmatched by other synthetic biology companies Harness the power of evolution.” sacred goal, CEO of Primrose Bio. “This platform will enable the discovery and production of new complex therapeutics and vaccines, and we are excited to offer our expanded capabilities to our partners through this merger.”
Primrose Bio’s technology has been used to launch Prima RNApols™ and PeliCRM197®provides two broadly licensed manufacturing and formulation solutions to biopharmaceutical companies developing mRNA medicines and conjugate vaccines, respectively.
“We discovered that nature is often smarter than us, and our platform is designed to let biology do the heavy lifting. We generated collections of novel microorganisms and proteins with orders of magnitude more genetic diversity than is currently feasible using other methods . This allows us to find microorganisms, enzymes and proteins with desirable characteristics that might be missed using traditional methods.” Diane Retalek
, President of Primrose Bio. “Primrose Bio is at an exciting time, with more and more biopharmaceutical companies using our technology and multiple projects in development that could transform biopharmaceutical manufacturing.”
Primrose Bio’s initial focus areas include:
- Work with the biopharmaceutical industry to leverage our technology to optimize production of hosts, enzymes and proteins and support partners’ process design and scale-up needs;
- Commercializing Prima RNApols™ and PeliCRM197® Enables mRNA drugs and conjugate vaccines respectively;
- Develop translational manufacturing methods, including enzymatic oligonucleotide synthesis for oligonucleotide-based therapeutics and enhanced microbial production of complex therapeutic proteins such as non-glycosylated antibodies, antibody derivatives, and Fc fusions;
- Expand our technologies beyond human health into sustainable food, energy, industrial and consumer products.
About Primrose Bio, Inc.
Primrose Bio was formed in 2023 from the merger of Primordial Genetics, Inc. and Pelican Technology Holdings, Inc. Primrose Bio combines Function Generator™ and Pelican Expression Technology® Platform creates a new way to enhance biological productivity to enable next-generation therapeutics. These combined technologies are designed to create and express the largest sets of genetic diversity in the industry, enabling customers to discover new biomolecules and cells at levels of productivity that were previously unattainable, economically unattainable, or unavailable. Primrose leverages its technology to create Prima RNApols™ and PeliCRM197®, two manufacturing and formulation solutions licensed to biopharmaceutical companies developing mRNA drugs and conjugate vaccines, respectively. Primrose Bio’s technology is used by many of the world’s leading pharmaceutical companies, including Merck, Jazz Pharmaceuticals, Alvogen, Serum Institute of India, Arcellx, Arcturus et al. For more information, please visit www.primrosebio.com.
View original content to download multimedia: https://www.prnewswire.com/news-releases/introducing-primrose-bio-enabling-innovative-therapeutic-discovery-and-manufacturing-301931130.html
Content provided by PR Newswire. Toutiao is not responsible for the content provided or any links related to that content. Toutiao is not responsible for the accuracy, topicality or quality of the content.